Does Taltz Clear Plaque Psoriasis?
Taltz (ixekizumab) treats moderate to severe plaque psoriasis in adults and children 6 and older. In phase 3 trials like UNCOVER-1, UNCOVER-2, and UNCOVER-3, 80-90% of patients achieved at least 75% skin clearance (PASI 75) after 12 weeks, compared to 3-10% on placebo.[1][2] Nearly 60% reached near-complete clearance (PASI 90), and 30-40% achieved fully clear skin (PASI 100).[1]
How Quickly Does Taltz Work?
Patients see improvements within week 1, with 60-80% PASI 75 response by week 4 and sustained results through 60 weeks in long-term studies.[1][3] Induction dosing is 160 mg at week 0, then 80 mg every 2 weeks for 12 weeks, followed by every 4 weeks.
Taltz vs. Other Biologics for Psoriasis
Taltz outperforms etanercept (Enbrel) in head-to-head trials, with 82% PASI 75 at week 12 vs. 39% for Enbrel.[1] It matches or exceeds adalimumab (Humira) and ustekinumab (Stelara) in skin clearance but excels in scalp and nail psoriasis.[4] Secukinumab (Cosentyx), another IL-17 inhibitor, shows similar efficacy (80-85% PASI 75).[4]
| Drug | PASI 75 at Week 12 | Key Differentiator |
|------|---------------------|-------------------|
| Taltz | 80-90% | Fast onset, nails/scalp |
| Cosentyx | 80-85% | Also IL-17, similar profile |
| Stelara | 65-75% | IL-12/23, fewer infections |
| Humira | 70-80% | TNF, broader approvals |
Common Side Effects and Risks
Upper respiratory infections affect 15-20% of users, with yeast infections in 2-5%.[1] Serious risks include inflammatory bowel disease (0.5-1%) and hypersensitivity reactions. Long-term data show low malignancy rates, comparable to placebo.[3] Not for active Crohn's or ulcerative colitis patients.
Who Responds Best and Who Doesn't?
Best for moderate-severe plaque psoriasis failing topicals or phototherapy. Responders often have higher baseline severity. Non-responders (10-20%) may switch to IL-23 inhibitors like risankizumab (Skyrizi).[4] Safe in pregnancy category unknown; use contraception.[1]
Cost and Access
Annual U.S. list price exceeds $80,000, but copay cards reduce it to $0-5 for eligible insured patients.[5] Covered by most plans; patient assistance via Lilly's program for uninsured.
[1]: Taltz prescribing information, Eli Lilly (ixekizumab.com)
[2]: Gordon et al., NEJM 2016 (UNCOVER trials)
[3]: Reich et al., J Am Acad Dermatol 2017 (long-term efficacy)
[4]: Griffiths et al., Lancet 2021 (biologic comparisons)
[5]: Drugs.com pricing data